Nature Reviews Drug Discovery
@natrevdrugdiscov.nature.com
Editorial team of Nature Reviews Drug Discovery
www.nature.com/nrd
www.nature.com/nrd
Epigenetic editing: from concept to clinic
rdcu.be/eRJBO
www.nature.com/articles/s41...
Epigenetic editing aims to reprogramme gene expression by rewriting epigenetic signatures, without editing of the genome. Find out about progress in the field in this new Review
rdcu.be/eRJBO
www.nature.com/articles/s41...
Epigenetic editing aims to reprogramme gene expression by rewriting epigenetic signatures, without editing of the genome. Find out about progress in the field in this new Review
November 25, 2025 at 3:16 PM
Epigenetic editing: from concept to clinic
rdcu.be/eRJBO
www.nature.com/articles/s41...
Epigenetic editing aims to reprogramme gene expression by rewriting epigenetic signatures, without editing of the genome. Find out about progress in the field in this new Review
rdcu.be/eRJBO
www.nature.com/articles/s41...
Epigenetic editing aims to reprogramme gene expression by rewriting epigenetic signatures, without editing of the genome. Find out about progress in the field in this new Review
Advancing pharmacogenomics in medicines regulation and clinical practice: a call for collaborative action
www.nature.com/articles/d41...
This new Comment article presents recommendations to address barriers to the implementation of pharmacogenomics
www.nature.com/articles/d41...
This new Comment article presents recommendations to address barriers to the implementation of pharmacogenomics
November 24, 2025 at 2:58 PM
Advancing pharmacogenomics in medicines regulation and clinical practice: a call for collaborative action
www.nature.com/articles/d41...
This new Comment article presents recommendations to address barriers to the implementation of pharmacogenomics
www.nature.com/articles/d41...
This new Comment article presents recommendations to address barriers to the implementation of pharmacogenomics
For readers interested in the frontiers of cell therapies for cancer, here's a review on in vivo CAR-T cells, which could address some of the limitations of the approved ex vivo therapies
rdcu.be/eQ9Ho
www.nature.com/articles/s41...
rdcu.be/eQ9Ho
www.nature.com/articles/s41...
In vivo chimeric antigen receptor (CAR)-T cell therapy
Nature Reviews Drug Discovery - In vivo chimeric antigen receptor (CAR)-T cell engineering uses targeted delivery systems to generate CAR-T cells directly in patients, bypassing ex vivo...
rdcu.be
November 21, 2025 at 3:40 PM
For readers interested in the frontiers of cell therapies for cancer, here's a review on in vivo CAR-T cells, which could address some of the limitations of the approved ex vivo therapies
rdcu.be/eQ9Ho
www.nature.com/articles/s41...
rdcu.be/eQ9Ho
www.nature.com/articles/s41...
Accelerating progress in immune cell therapy for solid tumours www.nature.com/articles/d41...
This Comment article discusses how collaborative translational research and adaptive clinical trial design are needed to advance novel T cell therapies towards achieving cures in solid tumours
This Comment article discusses how collaborative translational research and adaptive clinical trial design are needed to advance novel T cell therapies towards achieving cures in solid tumours
November 21, 2025 at 3:35 PM
Accelerating progress in immune cell therapy for solid tumours www.nature.com/articles/d41...
This Comment article discusses how collaborative translational research and adaptive clinical trial design are needed to advance novel T cell therapies towards achieving cures in solid tumours
This Comment article discusses how collaborative translational research and adaptive clinical trial design are needed to advance novel T cell therapies towards achieving cures in solid tumours
Targeting the Hippo pathway in cancer
rdcu.be/eQL6l
nature.com/articles/s41...
This Review in the November issue discusses Hippo pathway-targeted therapies, particularly those that target TEAD proteins and their interaction with the YAP/TAZ transcription co-activators
rdcu.be/eQL6l
nature.com/articles/s41...
This Review in the November issue discusses Hippo pathway-targeted therapies, particularly those that target TEAD proteins and their interaction with the YAP/TAZ transcription co-activators
November 19, 2025 at 2:57 PM
Targeting the Hippo pathway in cancer
rdcu.be/eQL6l
nature.com/articles/s41...
This Review in the November issue discusses Hippo pathway-targeted therapies, particularly those that target TEAD proteins and their interaction with the YAP/TAZ transcription co-activators
rdcu.be/eQL6l
nature.com/articles/s41...
This Review in the November issue discusses Hippo pathway-targeted therapies, particularly those that target TEAD proteins and their interaction with the YAP/TAZ transcription co-activators
For readers interested in therapeutic strategies based on inducing proximity between proteins, such as Halda's RIPTACs, here's a review on the field www.nature.com/articles/s41...
rdcu.be/eQzXF
and a news story on RIPTACs www.nature.com/articles/d41...
rdcu.be/eQzXF
and a news story on RIPTACs www.nature.com/articles/d41...
Induced proximity-based therapeutic modalities - Nature Reviews Drug Discovery
Induced proximity modalities encompass monovalent and bifunctional agents, such as molecular glues and proteolysis-targeting chimeras, that induce an interaction between biomolecules to functionally m...
www.nature.com
November 18, 2025 at 3:25 PM
For readers interested in therapeutic strategies based on inducing proximity between proteins, such as Halda's RIPTACs, here's a review on the field www.nature.com/articles/s41...
rdcu.be/eQzXF
and a news story on RIPTACs www.nature.com/articles/d41...
rdcu.be/eQzXF
and a news story on RIPTACs www.nature.com/articles/d41...
Reposted by Nature Reviews Drug Discovery
Johnson & Johnson said Monday it will purchase Halda Therapeutics and its experimental prostate cancer drugs for $3.05 billion. www.statnews.com/2025/11/17/h...
Johnson & Johnson acquires Halda Therapeutics for $3 billion, a big win for a buzzy new technology
Johnson & Johnson said it will purchase Halda Therapeutics, marking the first major buyout for a cancer drugmaker built around so-called PROTACs, a buzzy new technology.
www.statnews.com
November 17, 2025 at 7:13 PM
Johnson & Johnson said Monday it will purchase Halda Therapeutics and its experimental prostate cancer drugs for $3.05 billion. www.statnews.com/2025/11/17/h...
FDA approves 100th small-molecule kinase inhibitor www.nature.com/articles/d41...
From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes
From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes
November 17, 2025 at 3:12 PM
FDA approves 100th small-molecule kinase inhibitor www.nature.com/articles/d41...
From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes
From the landmark approval of the anticancer drug imatinib almost a quarter century ago, our latest news feature analyses trends in the field of kinase inhibitors, now one of the major drug classes
For readers interested in GLP-1-based therapies for diabetes, obesity and beyond, here's a recent review
rdcu.be/ePXoK
www.nature.com/articles/s41...
rdcu.be/ePXoK
www.nature.com/articles/s41...
GLP-1-based therapies for diabetes, obesity and beyond
Nature Reviews Drug Discovery - GLP-1-based therapies represent highly effective treatments for patients with type 2 diabetes and obesity. This Review profiles established and emerging GLP-1-based...
rdcu.be
November 14, 2025 at 4:28 PM
For readers interested in GLP-1-based therapies for diabetes, obesity and beyond, here's a recent review
rdcu.be/ePXoK
www.nature.com/articles/s41...
rdcu.be/ePXoK
www.nature.com/articles/s41...
Lilly’s tirzepatide and Novo Nordisk’s semaglutide vie for top drug spot nature.com/articles/d41...
The two GLP-1-based therapies for diabetes and obesity are set to overtake the current market-leading cancer immunotherapy pembrolizumab
The two GLP-1-based therapies for diabetes and obesity are set to overtake the current market-leading cancer immunotherapy pembrolizumab
November 14, 2025 at 4:25 PM
Lilly’s tirzepatide and Novo Nordisk’s semaglutide vie for top drug spot nature.com/articles/d41...
The two GLP-1-based therapies for diabetes and obesity are set to overtake the current market-leading cancer immunotherapy pembrolizumab
The two GLP-1-based therapies for diabetes and obesity are set to overtake the current market-leading cancer immunotherapy pembrolizumab
Reposted by Nature Reviews Drug Discovery
New from the @hansclevers.bsky.social group Drug screening and human organoids @natrevdrugdiscov.nature.com www.nature.com/articles/s41...
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges - Nature Reviews Drug Discovery
Human organoids provide physiologically relevant, 3D models for studying disease mechanisms, drug efficacy and toxicity. This Review examines organoid generation methods, applications in preclinical d...
www.nature.com
November 12, 2025 at 12:15 PM
New from the @hansclevers.bsky.social group Drug screening and human organoids @natrevdrugdiscov.nature.com www.nature.com/articles/s41...
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges
www.nature.com/articles/s41...
rdcu.be/ePz9n
This new Review by Clevers et al. discusses organoid generation methods and uses in preclinical drug discovery, as well as the regulatory and practical challenges
www.nature.com/articles/s41...
rdcu.be/ePz9n
This new Review by Clevers et al. discusses organoid generation methods and uses in preclinical drug discovery, as well as the regulatory and practical challenges
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges - Nature Reviews Drug Discovery
Human organoids provide physiologically relevant, 3D models for studying disease mechanisms, drug efficacy and toxicity. This Review examines organoid generation methods, applications in preclinical d...
www.nature.com
November 12, 2025 at 3:12 PM
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges
www.nature.com/articles/s41...
rdcu.be/ePz9n
This new Review by Clevers et al. discusses organoid generation methods and uses in preclinical drug discovery, as well as the regulatory and practical challenges
www.nature.com/articles/s41...
rdcu.be/ePz9n
This new Review by Clevers et al. discusses organoid generation methods and uses in preclinical drug discovery, as well as the regulatory and practical challenges
This article in the November issue discusses the changing landscape of medicinal chemistry optimization based on analysis of sets of hits, leads and drug candidates, which reveals shifts in key physicochemical properties
rdcu.be/ePoB9
www.nature.com/articles/s41...
rdcu.be/ePoB9
www.nature.com/articles/s41...
The changing landscape of medicinal chemistry optimization
Nature Reviews Drug Discovery - Medicinal chemistry optimizations in the progression from hit to lead to drug candidate affect properties of small-molecule drugs such as their molecular weight and...
rdcu.be
November 11, 2025 at 3:23 PM
This article in the November issue discusses the changing landscape of medicinal chemistry optimization based on analysis of sets of hits, leads and drug candidates, which reveals shifts in key physicochemical properties
rdcu.be/ePoB9
www.nature.com/articles/s41...
rdcu.be/ePoB9
www.nature.com/articles/s41...
For readers interested in therapies that harness regulatory T cells to treat disease, here's a review on this topic rdcu.be/ePb76 www.nature.com/articles/s41...
and a review discussing their potential to reset the immune system rdcu.be/ePb8b www.nature.com/articles/s41...
and a review discussing their potential to reset the immune system rdcu.be/ePb8b www.nature.com/articles/s41...
Harnessing the biology of regulatory T cells to treat disease
Nature Reviews Drug Discovery - Regulatory T cells keep the immune system in check to maintain homeostasis and restrain inflammation. This Review discusses strategies to harness these cells...
rdcu.be
November 10, 2025 at 3:23 PM
For readers interested in therapies that harness regulatory T cells to treat disease, here's a review on this topic rdcu.be/ePb76 www.nature.com/articles/s41...
and a review discussing their potential to reset the immune system rdcu.be/ePb8b www.nature.com/articles/s41...
and a review discussing their potential to reset the immune system rdcu.be/ePb8b www.nature.com/articles/s41...
“It’s about time”: Tregs win the Nobel prize
www.nature.com/articles/d41...
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of therapies based on regulatory T cells in this new interview
www.nature.com/articles/d41...
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of therapies based on regulatory T cells in this new interview
“It’s about time”: Tregs win the Nobel prize
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of Treg therapies.
www.nature.com
November 10, 2025 at 3:15 PM
“It’s about time”: Tregs win the Nobel prize
www.nature.com/articles/d41...
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of therapies based on regulatory T cells in this new interview
www.nature.com/articles/d41...
Jeff Bluestone, CEO of Sonoma Biotherapeutics, discusses the past and future of therapies based on regulatory T cells in this new interview
For readers interested in bispecific antibodies as cancer therapies, here's a review
rdcu.be/eOONr
www.nature.com/articles/s41...
rdcu.be/eOONr
www.nature.com/articles/s41...
The present and future of bispecific antibodies for cancer therapy
Nature Reviews Drug Discovery - Bispecific antibodies (bsAbs) can mediate therapeutic effects beyond those of natural monospecific antibodies. This Review provides an overview of recent...
rdcu.be
November 7, 2025 at 3:43 PM
For readers interested in bispecific antibodies as cancer therapies, here's a review
rdcu.be/eOONr
www.nature.com/articles/s41...
rdcu.be/eOONr
www.nature.com/articles/s41...
Innovative antibody therapeutic development in China compared with the USA and Europe nature.com/articles/d41...
Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development
Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development
Innovative antibody therapeutic development in China compared with the USA and Europe
Discover the world’s best science and medicine | Nature.com
nature.com
November 7, 2025 at 3:40 PM
Innovative antibody therapeutic development in China compared with the USA and Europe nature.com/articles/d41...
Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development
Data indicate that China’s focus on policy-driven innovation is enabling companies based there to surpass those in the USA and Europe in ADC and bispecific development
Cancer cell therapies: global clinical trial trends and emerging directions www.nature.com/articles/d41...
This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field
This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field
Cancer cell therapies: global clinical trial trends and emerging directions
Discover the world’s best science and medicine | Nature.com
www.nature.com
November 6, 2025 at 3:54 PM
Cancer cell therapies: global clinical trial trends and emerging directions www.nature.com/articles/d41...
This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field
This new article byanalyses trends across trial phases, indications, modalities, cell sources and targets to map the current trajectory of the field
For readers interested in the development of drugs for fibrotic diseases such as idiopathic pulmonary fibrosis, here's a review discussing the underlying biology and how to address the translational research challenges
rdcu.be/eOpGH
www.nature.com/articles/s41...
rdcu.be/eOpGH
www.nature.com/articles/s41...
Fibrosis: cross-organ biology and pathways to development of innovative drugs
Nature Reviews Drug Discovery - Fibrosis is a key characteristic of a range of chronic diseases that has been challenging to target with drugs. This Review highlights core pathways active in...
rdcu.be
November 5, 2025 at 3:39 PM
For readers interested in the development of drugs for fibrotic diseases such as idiopathic pulmonary fibrosis, here's a review discussing the underlying biology and how to address the translational research challenges
rdcu.be/eOpGH
www.nature.com/articles/s41...
rdcu.be/eOpGH
www.nature.com/articles/s41...
FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis www.nature.com/articles/d41...
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
November 5, 2025 at 3:35 PM
FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis www.nature.com/articles/d41...
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
Induced proximity-based therapeutic modalities
nature.com/articles/s41...
rdcu.be/eOfBH
This new Review by @dannomura.bsky.social et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more
nature.com/articles/s41...
rdcu.be/eOfBH
This new Review by @dannomura.bsky.social et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more
Induced proximity-based therapeutic modalities - Nature Reviews Drug Discovery
Induced proximity modalities encompass monovalent and bifunctional agents, such as molecular glues and proteolysis-targeting chimeras, that induce an interaction between biomolecules to functionally m...
nature.com
November 4, 2025 at 4:12 PM
Induced proximity-based therapeutic modalities
nature.com/articles/s41...
rdcu.be/eOfBH
This new Review by @dannomura.bsky.social et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more
nature.com/articles/s41...
rdcu.be/eOfBH
This new Review by @dannomura.bsky.social et al. discusses the rapidly expanding landscape of therapeutic approaches based on inducing proximity between proteins, including targeted protein degraders and more
For readers interested in new drugs for chronic obstructive pulmonary disease, affecting proteins such as IL-33 and TSLP that are targeted by the bispecific involved in Roche's $1 billion deal with Qyuns Therapeutics, here's a review
rdcu.be/eN4SK
www.nature.com/articles/s41...
rdcu.be/eN4SK
www.nature.com/articles/s41...
November 3, 2025 at 4:31 PM
For readers interested in new drugs for chronic obstructive pulmonary disease, affecting proteins such as IL-33 and TSLP that are targeted by the bispecific involved in Roche's $1 billion deal with Qyuns Therapeutics, here's a review
rdcu.be/eN4SK
www.nature.com/articles/s41...
rdcu.be/eN4SK
www.nature.com/articles/s41...
Reposted by Nature Reviews Drug Discovery
Roche turns to China's Qyuns for preclinical respiratory asset in over $1B deal $RHHBY firstwordpharma.com/story/6511061
October 30, 2025 at 5:30 PM
Roche turns to China's Qyuns for preclinical respiratory asset in over $1B deal $RHHBY firstwordpharma.com/story/6511061
Our November issue is live! Read more about drugs for cancer cachexia, RNA chemistry and therapeutics, targeting the Hippo pathway in cancer, the changing landscape of medicinal chemistry optimization and more here www.nature.com/nrd/volumes/...
October 30, 2025 at 2:42 PM
Our November issue is live! Read more about drugs for cancer cachexia, RNA chemistry and therapeutics, targeting the Hippo pathway in cancer, the changing landscape of medicinal chemistry optimization and more here www.nature.com/nrd/volumes/...
For readers interested in new drugs for chronic obstructive pulmonary disease, here's a comprehensive review
rdcu.be/eNiYv
www.nature.com/articles/s41...
rdcu.be/eNiYv
www.nature.com/articles/s41...
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
Nature Reviews Drug Discovery - Chronic obstructive pulmonary disease (COPD) is a progressive and severe respiratory disease featuring airway obstruction and recurrent exacerbations, driven by a...
rdcu.be
October 29, 2025 at 3:04 PM
For readers interested in new drugs for chronic obstructive pulmonary disease, here's a comprehensive review
rdcu.be/eNiYv
www.nature.com/articles/s41...
rdcu.be/eNiYv
www.nature.com/articles/s41...